Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 7NIH 2NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Brain Neoplasms 206Glioblastoma 169Central Nervous System Neoplasms 138Astrocytoma 135Gliosarcoma 132Neuroblastoma 109Glioma 104Oligodendroglioma 87Medulloblastoma 68Sarcoma 51Neoplasms 45Ependymoma 43Osteosarcoma 40Wilms Tumor 39Familial ependymoma 38Neuroectodermal Tumors, Primitive, Peripheral 36Optic Nerve Glioma 33Breast Neoplasms 33Lymphoma, Non-Hodgkin 32Neurofibromatosis 1 31Choroid Plexus Neoplasms 29Lymphoma 28Burkitt Lymphoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Rhabdomyosarcoma 23Rhabdoid Tumor 23Recurrence 21Meningioma 21Carcinoma, Non-Small-Cell Lung 21Testicular Neoplasms 20

Interventions

temsirolimus 1entinostat 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Brain Stem Neoplasms × CNS × Clear all
NCT02780804 2023-10-17

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled 15 charts
CNSLymphoid

Lymphoma, Pinealoma, Central Nervous System Neoplasms, Brain Stem Neoplasms

NCT01182883 2017-07-02

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNS

Glioma, Pinealoma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡